Soluble Interleukin-2 Receptors in Patients with Advanced Colorectal Carcinoma

Pavlidis, Nicholas; Nicolaides, C.; Bairaktari, Eleni; Kalef-Ezra, J.; Athanassiadis, A; C, Seferiadis; Fountzilas, George

doi:10.1177/172460089601100102

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secretion of IL-2 and reaction to IL-2 are decreased in tumor patients by as yet unknown reasons. Previous report has demonstrated that metastases are related to the IL-2 level, and the tumor immune mediated by IL is decreased in favor of carcinogenesis, growth, diffusion and metastasis of tumor [6][7][8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

Transfection of IL-2 and/or IL-12 genes into spleen in treatment of rat liver cancer

You¹,

Wang²,

Yang³

et al. 2004

WJG

View full text Add to dashboard Cite

IL-2 and/or IL-12 genes injected directly into spleen increase serum IL-2 and IL-12 levels and enhance the NK cell activity, which may inhibit the liver tumor growth. The therapy of fused gene IL-2/IL-12 is of low toxicity and relatively high NK cell activity. Our data suggest that IL-2/IL-12 fused gene may be a safe and efficient gene therapy for liver tumor. The gene therapy should be administrated as early as possible.

show abstract

Section: Introductionmentioning

confidence: 99%

Transfection of IL-2 and/or IL-12 genes into spleen in treatment of rat liver cancer

You¹,

Wang²,

Yang³

et al. 2004

WJG

View full text Add to dashboard Cite

show abstract

“…Increased levels of sIL-2R and IL-2Rα are observed in several cancers, including colorectal, prostate, breast, and lung cancer [ 204 – 207 ], often indicating a poor prognosis. Moreover, they serve as potential diagnostic markers as elevated levels of sIL-2R and IL-2Rα have been detected in patients with colorectal cancer and those at increased risk of prostate cancer [ 189 , 208 ]. Further, these markers have potential utility in monitoring treatment efficacy.…”

Section: Soluble Il-2r (Sil-2r) and Il-2rα: Emerging Biomarkers And T...mentioning

confidence: 99%

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

et al. 2023

View full text Add to dashboard Cite

Interleukin-2 (IL-2) and its receptor (IL-2R) are essential in orchestrating immune responses. Their function and expression in the tumor microenvironment make them attractive targets for immunotherapy, leading to the development of IL-2/IL-2R-targeted therapeutic strategies. However, the dynamic interplay between IL-2/IL-2R and various immune cells and their dual roles in promoting immune activation and tolerance presents a complex landscape for clinical exploitation. This review discusses the pivotal roles of IL-2 and IL-2R in tumorigenesis, shedding light on their potential as diagnostic and prognostic markers and their therapeutic manipulation in cancer. It underlines the necessity to balance the anti-tumor activity with regulatory T-cell expansion and evaluates strategies such as dose optimization and selective targeting for enhanced therapeutic effectiveness. The article explores recent advancements in the field, including developing genetically engineered IL-2 variants, combining IL-2/IL-2R-targeted therapies with other cancer treatments, and the potential benefits of a multidimensional approach integrating molecular profiling, immunological analyses, and clinical data. The review concludes that a deeper understanding of IL-2/IL-2R interactions within the tumor microenvironment is crucial for realizing the full potential of IL-2-based therapies, heralding the promise of improved outcomes for cancer patients.

show abstract